209 related articles for article (PubMed ID: 27299795)
21. Ovarian Brenner tumors and transitional cell carcinoma: recent developments.
Roth LM; Gersell DJ; Ulbright TM
Int J Gynecol Pathol; 1993 Apr; 12(2):128-33. PubMed ID: 8463036
[TBL] [Abstract][Full Text] [Related]
22. Transitional cell neoplasms of the ovary and urinary bladder: a comparative immunohistochemical analysis.
Soslow RA; Rouse RV; Hendrickson MR; Silva EG; Longacre TA
Int J Gynecol Pathol; 1996 Jul; 15(3):257-65. PubMed ID: 8811388
[TBL] [Abstract][Full Text] [Related]
23. TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR.
Wang K; Liu T; Ge N; Liu L; Yuan X; Liu J; Kong F; Wang C; Ren H; Yan K; Hu S; Xu Z; Björkholm M; Fan Y; Zhao S; Liu C; Xu D
Oncotarget; 2014 Dec; 5(23):12428-39. PubMed ID: 25474136
[TBL] [Abstract][Full Text] [Related]
24. Transitional cell carcinoma of the endometrium associated with benign ovarian brenner tumor: a case report with immunohistochemistry molecular analysis and a review of the literature.
Giordano G; D'Adda T; Gnetti L; Merisio C; Raboni S
Int J Gynecol Pathol; 2007 Jul; 26(3):298-304. PubMed ID: 17581415
[TBL] [Abstract][Full Text] [Related]
25. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
[TBL] [Abstract][Full Text] [Related]
26. Ovarian Brenner tumors. I. Metaplastic, proliferating, and of low malignant potential.
Roth LM; Dallenbach-Hellweg G; Czernobilsky B
Cancer; 1985 Aug; 56(3):582-91. PubMed ID: 4005815
[TBL] [Abstract][Full Text] [Related]
27. [Malignant Brenner tumor and transitional cell carcinoma of the ovary].
Guo LN; Tang MY
Zhonghua Bing Li Xue Za Zhi; 1990 Sep; 19(3):209-11. PubMed ID: 2279315
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneity of TERT promoter mutations status in squamous cell carcinomas of different anatomical sites.
Cheng KA; Kurtis B; Babayeva S; Zhuge J; Tantchou I; Cai D; Lafaro RJ; Fallon JT; Zhong M
Ann Diagn Pathol; 2015 Jun; 19(3):146-8. PubMed ID: 25862495
[TBL] [Abstract][Full Text] [Related]
29. TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma.
Mannan R; Taylor AS; Spratt DE; Chinnaiyan AM; Montgomery JS; Brown NA; Mehra R
Pathol Res Pract; 2020 Jan; 216(1):152663. PubMed ID: 31630874
[TBL] [Abstract][Full Text] [Related]
30. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
[TBL] [Abstract][Full Text] [Related]
31. [Benign and malignant Brenner tumor of the ovary: a clinicopathological and immunohistochemical study].
Peng ZN
Zhonghua Bing Li Xue Za Zhi; 1992 Dec; 21(6):333-5. PubMed ID: 1284387
[TBL] [Abstract][Full Text] [Related]
32. Disappearance of Upper Urinary Tract Urothelial Carcinoma after Treatment of a Borderline Brenner Tumor: Case Report and Literature Review.
Aoun F; Kourie HR; Sirtaine N; Hawaux E
Oncol Res Treat; 2015; 38(7-8):379-81. PubMed ID: 26278583
[TBL] [Abstract][Full Text] [Related]
33. Transitional cell tumors of the ovary: a compact group with a heterogeneous histological and immunophenotypical pattern.
Ceauşu M; Terzea D; Georgescu A; Dobrea C; Mihai M; Iosif C; Vasilescu F; Ardeleanu C
Rom J Morphol Embryol; 2008; 49(4):513-6. PubMed ID: 19050800
[TBL] [Abstract][Full Text] [Related]
34. Transitional cell tumor of the ovary: computed tomographic and magnetic resonance imaging features with pathological correlation.
Oh SN; Rha SE; Jung SE; Lee YJ; Choi BG; Byun JY; Ku YM; Jung CK
J Comput Assist Tomogr; 2009; 33(1):106-12. PubMed ID: 19188796
[TBL] [Abstract][Full Text] [Related]
35. Borderline Brenner Tumor: A Review of the Literature.
Zheng R; Heller DS
Arch Pathol Lab Med; 2019 Oct; 143(10):1278-1280. PubMed ID: 30779594
[TBL] [Abstract][Full Text] [Related]
36. Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers.
Marchese PV; Mollica V; Tassinari E; De Biase D; Giunchi F; Marchetti A; Rosellini M; Fiorentino M; Massari F
Expert Rev Mol Diagn; 2022 Nov; 22(11):997-1008. PubMed ID: 36503370
[TBL] [Abstract][Full Text] [Related]
37. Brenner tumor of the ovary: a comparative immunohistochemical and ultrastructural study with transitional cell carcinoma of the bladder.
Ordóñez NG; Mackay B
Ultrastruct Pathol; 2000; 24(3):157-67. PubMed ID: 10914427
[TBL] [Abstract][Full Text] [Related]
38. Unusual presentation of benign cystic brenner tumor with exuberant psammomatous calcifications.
Vemavarapu L; Alatassi H; Moghadamfalahi M
Int J Surg Pathol; 2011 Feb; 19(1):120-2. PubMed ID: 21087980
[TBL] [Abstract][Full Text] [Related]
39. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer.
Avogbe PH; Manel A; Vian E; Durand G; Forey N; Voegele C; Zvereva M; Hosen MI; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Delhomme TM; Carreira C; Monteiro-Reis S; Henrique R; Abedi-Ardekani B; Byrnes G; Foll M; Weiderpass E; McKay J; Jeronimo C; Scelo G; Le Calvez-Kelm F
EBioMedicine; 2019 Jun; 44():431-438. PubMed ID: 31122840
[TBL] [Abstract][Full Text] [Related]
40. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.
Thiem S; Herold T; Krafft U; Bremmer F; Tolkach Y; Szász AM; Kriegsmann J; Gaisa NT; Niedworok C; Szarvas T; Reis H
Pathol Int; 2017 Dec; 67(12):597-601. PubMed ID: 29047227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
